UNSPSC 51432102: Guanadrel

This classification denotes an antihypertensive agent with the molecular formula C10H19N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 765C9332T4, chemically known as (1,4-dioxaspiro(4.5)dec-2-ylmethyl)guanidine but generally known as guanadrel, which bears US NIH Compound Identifier 38521. European Medicines Agency schedules Guanadrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07980MIG.

UNSPSC 51432102 Guanadrel is a Commodity code covering individual pharmaceutical products supplied to state and local health care and emergency-response operations. State and local governments buy specific medications under this code through competitive sealed-bid and cooperative-purchasing vehicles to support fire-rescue operations, pharmacy benefit programs, and multi-jurisdictional health care delivery. The issuing bodies include municipal fire departments (via city purchasing offices), state health and human services agencies, and regional cooperative purchasing alliances that aggregate demand across multiple states and local jurisdictions. Scope varies from small, specific-unit procurements for emergency medications to large multi-product generic and over-the-counter pharmaceutical contracts serving statewide and interstate networks of facilities.

Recent activity shows activity concentrated in Florida and Minnesota, with cross-state cooperative reach. The City of Tampa Fire Rescue issued IFB 26P00188 (closed April 8, 2026) for four specific Advanced Life Support medications in quantities ranging from 330 to 1,810 units, with an estimated contract value of $40,000 and a one-year term plus renewal options. The Texas Health and Human Services Commission posted RFI HHS0017013 to gather vendor capabilities for direct-to-manufacturer prescription programs—a preliminary market-intelligence phase with no award value specified at this stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with contract terms effective July 1, 2026. MMCAP requires vendors to work through three authorized wholesalers and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, with performance penalties of $200 to $1,500 per violation. Cooperative purchasing vehicles, such as MMCAP, show repeated use as a procurement method for achieving scale across jurisdictions while maintaining individual agency flexibility in product selection and ordering.